Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Phase I Clinical Study of HBx-based mRNA Vaccine (WGc-0201 Injection) Plus Tislelizumab in Hepahepatocellular Carcinoma With High Risk of Recurrence and Metastasis After Radical Therapy

NCT07077369 is registered in ClinicalTrials.gov with West China Hospital as lead sponsor.

NCT NCT07077369
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT07077369 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Phase I Clinical Study of HBx-based mRNA Vaccine (WGc-0201 Injection) Plus Tislelizumab in Hepahepatocellular Carcinoma With High Risk of Recurrence and Metastasis After Radical Therapy
Lead sponsor
West China Hospital
Phase
Phase 1
Overall status
Not yet recruiting
Start date
August 1, 2025
Completion date
December 31, 2028
Enrollment
10 (estimated)
Sites
Not reported

Conditions

As the registry lists them; a condition with its own page is linked.

hepatocellular carcinoma (hcc)